A press release states that restor3d Inc. completed the acquisition after restor3d shareholders approved it.
According to the press release, Conformis’ common stock ceased trading at the NASDAQ on September 5.
“We are extremely excited to complete this important transaction and look forward to leveraging our combined portfolio to deliver personalized orthopedic solutions for the whole human body,” J. Kurt Jacobus, CEO of restor3d, said in the release. “With the addition of Conformis to the organization, we see tremendous opportunity to deliver
